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Germ-Line and
Somatic Presentations
of the EGFR T790M
Mutation in Lung
Cancer
To the Editor:
Somatic mutations in the kinase
domain of the epidermal growth factor
receptor (EGFR) gene are found in
about 10% of lung adenocarcinomas
that have been sequenced from Western
countries and in about 30% of those that
have been sequenced from Asia.1 EGFR
mutations are associated with sensitivity
to the EGFR tyrosine kinase inhibitors
gefitinib and erlotinib. However, many
patients who initially respond to treat-
ment with gefitinib or erlotinib develop
resistance to these inhibitors and subse-
quently relapse. This process has been
associated with point mutations in the
kinase domain of mutant EGFR.2,3 The
most common EGFR mutation associ-
ated with treatment resistance involves a
C-to-T change at nucleotide 2369 in
exon 20, which results in threonine-to-
methionine substitution at the amino
acid position 790 (T790M). This amino
acid change does not seem to diminish
EGFR’s catalytic activity, but the pres-
ence of the T790M mutation is predicted
to impair binding of either gefitinib or
erlotinib to the EGFR adenosine triphos-
phate-binding pocket.2,3 In addition,
emerging data suggest that the T790M
change may potentiate oncogenic activ-
ity. For example, a T790M germ-line
mutation was found in one family with a
high incidence of lung cancer,4 and so-
matic T790M mutations have been occa-
sionally detected in tumors from patients
who never received EGFR inhibitors.5 In
fact, it may be likely that all T790M
mutations are present in a small subset
of tumor cells before treatment and they
expand selectively with EGFR tyrosine
kinase inhibitors treatment. Using de-
oxyribonucleic acid (DNA) extracted
from formalin-fixed and paraffin-em-
bedded tissues from 240 patients with
lung adenocarcinomas that had never
received treatment with EGFR inhibi-
tors, we sequenced the EGFR exons 18
to 21 and identified 2 tumor cases (1%)
harboring the T790M mutation. Here,
we report those two cases with an un-
usual presentation of the T790M muta-
tion, including a germ-line and a so-
matic mutation (Figure 1).
The first case of T790M-associ-
ated lung cancer occurred in a 72-year-
old female never smoker presented with
3 synchronous lung tumors, 2 adenocar-
cinomas, and 1 large-cell neuroendo-
crine carcinoma with hilar lymph node
metastasis (Figures 1A–C). In addition
to the malignant tissue from the three
tumors, microdissected cells from nor-
mal bronchiolar epithelium, pleural con-
nective tissue, and nonmetastatic lymph
nodes showed the presence of both the
EGFR T790M and wild-type alleles. No
other EGFR mutations were detected in
the patient’s tissue specimens. We con-
firmed the presence of a germ-line mu-
tation by sequencing the DNA extracted
from the patient’s peripheral mononu-
clear blood cells. Although we were
unable to examine DNA from other
family members, this patient repre-
sents, to our knowledge, the second
case4 of a T790M germ-line mutation
ever reported and confirms the possibil-
ity that this phenomenon confers lung
cancer susceptibility.
The second case of T790M-asso-
ciated lung cancer occurred in a 62-year-
old female never smoker diagnosed with
stage IA adenocarcinoma; no other EGFR
activating mutation was seen (Figures
1D–F). The T790M mutation was not
detected in the DNA extracted from
multiple microdissected tissue samples,
including nonmalignant pleural connec-
tive tissue, lung hilar lymph nodes, and
breast connective tissue obtained during
a previous breast cancer resection show-
ing that mutation was somatic. However,
EGFR mutation analysis of microdis-
sected epithelium obtained from bronchio-
lar structures adjacent to the tumor
showed the T790M mutation in three out
of five histologically normal epithelium
sites. We previously demonstrated that
EGFR kinase domain mutations in ex-
ons 19 and 21 are sometimes detected in
normal bronchial and bronchiolar epithe-
lium adjacent to EGFR mutant lung tu-
mors, indicating that the development of
such mutations may be an early event in
the pathogenesis of lung adenocarcinoma
as a filed cancerization phenomenon.6 The
presence of the T790M mutation in the
normal bronchial epithelium in this patient
confirms this mutation’s potential onco-
genic effect, and its role in preneoplastic
lesions, which is supported by the report
that in vitro human bronchial epithelial
cells overexpressing the T790M mutation
showed a growth advantage over cells
expressing the wild-type form.7
Although the EGFR T790M muta-
tion has been identified in the context of
EGFR resistance to tyrosine kinase inhib-
itors, it is usually found in conjunction
with a classific EGFR TK domain activat-
ing mutation. In the two cases described in
this report, only the T790M mutation was
found. The presence of the mutation alone
and also its presence in prenoplastic le-
sions, indicate that the T790M mutation
can occasionally be found in patients
whose lung tumors exhibit primary drug
resistance and that this mutation may have
an oncogenic effect in lung respiratory
epithelial cells.
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FIGURE 1. Epidermal growth factor receptor (EGFR) T790M Mutation in Two Patients with Lung Cancer. Panel A, shows the pedi-
gree of the patient with the germ-line EGFR T790M mutation (the patient is indicated by the arrow, and lung cancer is indicated by
solid symbols). Panel B, shows a diagram of the patient’s lungs illustrating the three synchronous lung tumors and representative
microphotographs from histologic analysis (hematoxylin and eosin, magnification 400). Tumor 1 (T1) was an invasive adenocarci-
noma located in the right lower lobe, tumor 2 (T2) was a pure (noninvasive) bronchioloalveolar carcinoma (BAC) located in the
right middle lobe, and tumor 3 (T3) was a large-cell neuroendocrine carcinoma (LCNEC) located in the left lower lobe with hilar
lymph node metastasis. Deoxyribonucleic acid (DNA) was extracted from about 1000 microdissected cells from four sites in T1 and
1 site each from the T2 and T3 lymph node metastases (red circles) and then examined for EGFR mutations in exons 18 to 21. In
addition, microdissected connective pleural tissue (two sites), nonmetastatic lymph node (two sites), and normal bronchial epithe-
lium adjacent to T1 and T2 (7 sites) were also examined (sites not indicated). All the specimens, nonmalignant and malignant,
demonstrated the T790M mutation. Panel C, shows examples of nucleotide sequence tracings illustrating heterozygosity with re-
spect to the T790M mutation in DNA extracted from the peripheral mononuclear blood cells and the tissue sites examined. Panel
D, shows the pedigree of the patient with the somatic EGFR T790M mutation (the patient is indicated by the arrow, and lung can-
cer is indicated by the solid symbols). Panel E, shows a diagram of the patient’s lungs illustrating the tumor and representative mi-
crophotographs from histologic analysis of the normal epithelium and tumor (hematoxylin and eosin, magnification 400). In this
case, the T790M mutation was detected in four of the four tumor sites (T, red circles) and three of the five normal bronchial epithe-
lium sites (NE, mutant: red circles, wild-type: yellow circles). Microdissected tissue from two pleural (P, green circles) and lymph
node (LN, blue circles) sites without tumor involvement had the wild-type allele. Panel F, shows examples of nucleotide sequence
tracings illustrating heterozygosity with respect to the T790M variant in normal bronchiolar epithelium and tumor specimen sites.
The lymph node sites and pleural tissues had the wild-type allele.
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Complete Response of
Recurrent Squamous
Cell Carcinoma of the
Lung: Dose the Dose
Matter?
To the Editor:
Bevacizumab is a humanized
monoclonal antibody against vascular
endothelial growth factor and has shown
significant clinical benefit in patients
with various cancers.1 A randomized
phase II study comparing carboplatin
plus paclitaxel with or without bevaci-
zumab in non-small cell lung cancer
patients demonstrated that the addition
of bevacizumab results in an increase in
time to disease progression.2 However,
because of an increased risk of pulmo-
nary hemorrhage with bevacizumab
treatment, a subsequent large phase III
study excluded patients with squamous
cell histology.3 In this report, we present
an elderly patient with recurrent squa-
mous cell carcinoma of the lung who
achieved complete response after treat-
ment with bevacizumab plus carboplatin
and paclitaxel without developing any
hemorrhagic complications.
A 79-year-old man visited our
hospital in July of 2007 with cough and
sputum for a month. The patient under-
went a left upper lobe lobectomy in May
of 2005. Pathology revealed poorly dif-
ferentiated squamous cell carcinoma,
and was staged as T2N1M0. After sur-
gery, four cycles of vinorelbine plus
cisplatin adjuvant chemotherapy were
administered.
Upon admission, his Eastern Co-
operative Oncology Group (ECOG) per-
formance status was 2. Chest computed
tomography (CT) scan revealed recur-
rence of the disease in the left main
bronchus involving the carina, and a
large intraluminal-protruding mass for-
mation with internal necrosis (Figure 1).
Biopsy revealed a squamous cell carci-
noma, pathologically confirming disease
recurrence. Chemotherapy with bevaci-
zumab 7.5 mg/kg combined with carbo-
platin, area under the curve 4, and pacli-
taxel 175 mg/m2 was given once every 3
weeks for 4 cycles. CT scan after the
second cycle showed complete response
(Figure 2) without any evidence of pulmo-
nary hemorrhage. The CT scan after the
fourth cycle showed that complete remis-
sion was maintained. After completing the
regimen, the patient has been receiving
bevacizumab alone for an additional eight
cycles without evidence of recurrence.
The efficacy of bevacizumab in an-
giogenesis inhibition in non-small cell lung
cancer has already been documented,3,4
but comes at a significant price; it is often
associated with adverse side effects, in-
cluding pulmonary hemorrhage, which
may be a life-threatening condition. A
randomized phase II study conducted by
Johnson et al.2 warned of the risk of bleed-
ing in tumors of the squamous cell histol-
ogy, tumors located close to major vessels,
and tumors with necrosis or cativation.
Thus, a phase III trial (ECOG 4599) of
bevacizumab excluded patients with squa-
mous cell histology, brain metastasis, or
anticoagulation medications.3
This is the first case report of an
elderly patient with squamous cell his-
tology who showed complete response
after being treated by bevacizumab
combined with carboplatin and pacli-
taxel. This finding is significant in that
the patient had a higher risk for pulmo-
nary hemorrhage because he was el-
derly, had poor performance status, and
had squamous cell histology, which was
centrally located and showed necrosis.
A recent subset analysis of the ECOG
4599 trial revealed no survival benefits
of bevacizumab plus caboplatin and
paclitaxel for elderly patients (70
years). This finding can be explained by
the higher toxicity when adding bevaci-
zumab to chemotherapy compared with
chemotherapy alone.5
In our case, we used a lower dose
of bevacizumab (7.5 mg/kg), and an
attenuated dose of carboplatin (area un-
der the curve 4) and paclitaxel (175
mg/m2) compared with the ECOG 4599
trial.3 It seems that an attenuated dose of
chemotherapy and a lower dose of bevaci-
zumab can reduce the complications and
the toxicity. Further clinical studies will be
warranted to determine whether bevaci-
zumab is indeed a safe regimen in the
management of squamous cell carcinoma
of the lung and whether an attenuated dose
plays an important role in elderly patients.
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FIGURE 1. Computed tomography
(CT) scan at the time of recurrence. Ne-
crotic mass involved the posterior wall
of the proximal left main bronchus. Bi-
opsy was positive for recurrent squa-
mous cell carcinoma.
FIGURE 2. Computed tomography
(CT) scan after the second cycle of bev-
acizumab, carboplatin, and paclitaxel
chemotherapy. There was complete res-
olution of the necrotic mass involving
the left main stem bronchus.
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